Key result
Vasoactive intestinal peptide cuts proteinuria ~36% in lupus nephritis mice by restoring Th17/Treg balance.
Why the study?
Th17/Treg imbalance is a key factor in lupus nephritis development, and the role of vasoactive intestinal peptide in modulating this balance was investigated.
Does vasoactive intestinal peptide ameliorate renal injury and modulate Th17/Treg balance in a pristane-induced lupus mouse model?
Does vasoactive intestinal peptide ameliorate renal injury and modulate Th17/Treg balance in a pristane-induced lupus mouse model?
Vasoactive intestinal peptide ameliorates renal injury in a lupus nephritis mouse model by restoring the Th17/Treg cell balance and reducing inflammatory cytokines.
Answers are grounded in this paper and cite their sources.
Preclinical VIP data in lupus nephritis mice leave open human translation; prospective trials needed before any clinical consideration.
Lupus nephritis (LN) is an inflammation of the kidneys and is a major cause of mortality in systemic lupus erythaematosus (SLE) patients. In addition, Th17/Treg balance is one of the most important factors that can promote the development of LN. It has been reported that vasoactive intestinal peptide (VIP) is associated with the downregulation of both inflammatory and autoimmune diseases through regulating T lymphocyte balance. Therefore, the aim of this study was to determine the role of VIP in modulating Th17/Treg balance in LN. LN was induced in BALB/c female mice by injection pristane. After 3 months, mice were randomly divided into four groups: control, VIP + control, LN and VIP + LN. Autoantibody levels were tested by ELISA. The distribution of Th17/Treg cells in vivo and in vitro was detected by FC. Renal tissues were examined by PASM and DIF for pathology and Foxp3 + CD3 + . The mRNA and protein expression levels of pro- and anti-inflammatory cytokines were detected by qRT-PCR and western blotting. VIP can improve renal injury by regulating Th17/Treg imbalance in LN mice. Proteinuria, renal function defects and autoantibodies were significantly decreased, and Th17/Treg cell balance was restored in VIP compared with LN mice. In addition, VIP improved renal lesions by promoting the expression of Foxp3 + CD3 + in renal tissue. Furthermore, VIP downregulated the mRNA and protein expression of IL-17, IL-6 and upregulated Foxp3, IL-10 expression. VIP reduced LN proteinuria and renal function defects and restored the Th17/Treg cell balance. Furthermore, VIP also downregulated autoantibody and inflammatory cytokine expression and upregulated Foxp3 and IL-10 expression.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2019) studied Lupus nephritis (n=20). Vasoactive intestinal peptide (VIP) vs. Pristane-induced LN without VIP (saline control) was evaluated on 24 h proteinuria (mg/24 h) (p=<0.01). Vasoactive intestinal peptide significantly reduced 24-hour proteinuria and improved renal function by restoring Th17/Treg cell balance in a mouse model of lupus nephritis.
Synapse has enriched 10 related papers. Consider them for comparative context: